Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simultaneous multiple immunoassays in a compact disc-shaped microfluidic device based on centrifugal force.

Nobuo Honda1, Ulrika Lindberg, Per Andersson

  • 1Methodology Research Group, Research & Development Division, Fujirebio, Inc., Tokyo, Japan. no-honda@fujirebio.co.jp

Clinical Chemistry
|August 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Indication of Adjuvant Therapy Based on Oncotype DX Recurrence Score in Relation to Clinical and Pathological Factors, and Survival: A Retrospective Analysis of Real-World Use.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi·2026
Same author

[Asthma among athletes - prevalence, diagnosis and treatment].

Lakartidningen·2026
Same author

Treatment-naïve lung cancer presenting with spinal metastases: a national study of survival, surgery, and the role of predictive biomarkers.

Acta neurochirurgica·2026
Same author

Placenta-Specific miRNA miR-515-3p Suppresses HMGB3 Expression in the Breast Cancer Cell Line MCF-7.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi·2026
Same author

Evaluation of AgFON-based SERS combined with various headspace methods for the detection of thiol compounds in wine.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry·2026
Same author

Predictors of Pathologically Negative Sentinel Lymph Nodes and Recurrence-Free Survival in Women with Invasive Breast Cancer Treated with Neoadjuvant Chemotherapy.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi·2026

This study demonstrates a centrifugal microfluidic device for immunoassays using only 200 nL of sample. The platform achieves high precision and rapid antibody affinity analysis for biomarkers like AFP, IL-6, and CEA.

Area of Science:

  • Biomedical Engineering
  • Analytical Chemistry
  • Biotechnology

Background:

  • Microfluidic devices offer miniaturized platforms for biological assays.
  • Centrifugal force can be harnessed to control fluid dynamics in microfluidic systems.
  • Immunoassays are crucial for detecting biomarkers in various medical conditions.

Purpose of the Study:

  • To evaluate a centrifugal microfluidic device as a platform for high-precision immunoassays.
  • To assess the performance of the device using small sample volumes (200 nL).
  • To determine the feasibility of rapid antibody affinity ranking using fluorescence imaging.

Main Methods:

  • Antibodies against alpha-fetoprotein (AFP), interleukin-6 (IL-6), and carcinoembryonic antigen (CEA) were immobilized on streptavidin-coated particles within a microcolumn.

Related Experiment Videos

  • A 200-nL sample was processed through the microcolumn, followed by a labeled detection antibody.
  • Assay flow rate was controlled by rotational speed, enabling up to 104 sandwich immunoassays in 50 minutes.

    • Main Results:

    • Detection limits for AFP, IL-6, and CEA were 0.15, 1.25, and 1.31 pmol/L, respectively.
    • Inter- and intra-assay imprecisions (CVs) were <10% and <20% for concentrations >5 pmol/L.
    • Carcinogenic embryonic antigen (CEA) antibody showed the lowest affinity, confirmed by comparative BIAcore 3000 analysis.

    Conclusions:

    • The compact disc-shaped centrifugal microfluidic device achieves day-to-day imprecision (CV) of <20% for immunoassays.
    • Fluorescence image analysis provides a rapid method for ranking antibody affinities.
    • This platform demonstrates potential for efficient and precise biomarker detection.